---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-000860"
form_type: "8-K"
ticker: "AZTA"
cik: "0000933974"
company_name: "Azenta, Inc."
filed_at: "2024-02-07T23:59:59+00:00"
generated_at: "2026-06-06T07:35:53.307067+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Azenta Q1 rev $154M (-13% YoY), GAAP EPS ($0.28), non-GAAP $0.02; reaffirms FY24 guide

## Summary
- Revenue $154M, down 13% YoY; organic revenue -15%; combined Sample Mgmt & Multiomics grew 2% organic.
- GAAP diluted EPS from continuing ops ($0.28) vs ($0.15) prior year; non-GAAP diluted EPS $0.02 vs $0.12.
- B Medical revenue $13M, down 70% YoY (timing of orders); Sample Mgmt Solutions up 5%, Multiomics up 3%.
- FY2024 guidance reaffirmed: total revenue $696-$718M, non-GAAP EPS $0.19-$0.29, adj EBITDA margin +300bps.
- Repurchased 2.3M shares for $113M in Q1; plans additional $500M in FY2024 to complete $1.5B authorization.

## SEC filing metadata
- accession: 0001558370-24-000860
- form_type: 8-K
- ticker: AZTA
- cik: 0000933974
- company_name: Azenta, Inc.
- filed_at: 2024-02-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/933974/000155837024000860/0001558370-24-000860-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/933974/000155837024000860/azta-20240207x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-000860
- JSON: https://secwatch.observer/filing/0001558370-24-000860.json
- Plain text: https://secwatch.observer/filing/0001558370-24-000860.txt

## Key facts
- Earnings Releases
  Azenta, Inc. reported the first quarter ended December 31, 2023 results: revenue $ 154, net income $ (0.28), EPS $(0.28) per diluted share. Guidance reaffirmed.
  - Period: the first quarter ended December 31, 2023
  - Revenue: $ 154
  - Net income: $ (0.28)
  - EPS: $(0.28) per diluted share
  - Guidance: reaffirmed
  - Result: reported results
  source text: in millions, except per share data ​ December 31, ​ September 30, ​ December 31, ​ Change ​ ​ 2023 ​ 2023 ​ 2022 ​ Prior Qtr ​ Prior Yr. Revenue from Continuing Operations $ 154 ​ $ 172 $ 178 ​ (10) % ​ (13) % Organic growth ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (15) % Sample Management Solutions ​ $ 79 ​ $ 82 ​ $ 75 ​ (3) % ​ 5 % Multiomics ​ $ 63 ​ $ 61 ​ $ 61 ​ 3
  evidence_url: https://www.sec.gov/Archives/edgar/data/933974/000155837024000860/0001558370-24-000860-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.